History:

USPs:

Established in the year 1990

Established its first manufacturing facility in 1995
Built on a 500 acre site at Hyderabad (Unit-I)
the plant comprises of 13 multi-purpose
production blocks
Divis Laboratories set up its second manufacturing
facility at Visakhapatnam (Unit-II). in the year 2002 on a
350 acre site
The site has 14 multi purpose production blocks

Main aim of the Divis R&D Centers is to design, develop

and optimize commercially viable synthetic processes for
APIs and Intermediates of Generics
Company has obtained certification for being in
compliance with World Health Organisation

Corporate Governance:

Business Model:

July 15

IPR compliance
Established relationship for over 5 years with pharma
giants in Custom synthesis
Focus on regulated (premium) markets (Europe/USA)
Manufacture API's for the Generics
Actively involved in developing alternate, patent noninfringing processes for APIs
Supplies advanced intermediates for generic APIs

The Company has an Executive Chairman

Board comprises of eight directors, four of whom are
Executive and remaining are non-executive independent
directors, including a woman director, which is in
conformity with clause 49 of the listing agreement

Divis Laboratories

Sales & Sales Growth

Share Movement

350,000
308,401
41% 41%
300,000
251,397
212,395
250,000
183,949
23%
200,000
18%
130,544
15%
150,000
100,000
50,000
-

120
115
110
105
100
95
90
85
80

S&P

Sales

Divis

EBITDA & EBITDA Margin

140,000
120,000
100,000
80,000
60,000
40,000
20,000
-

43%
42%
41%
40% 40% 40%
39% 40%
39%
53,459 76,063 87,026110,276120,489 38%
37%

30%
20%
10%
0%

Sales Growth

300

30%

250
228.61

200
150
137.87
100
2010-11

July 15

40%

ROA & ROE

42%

EBITDA

50%

EBITDA Margin

163.85

22%
2012-13
ROA

24%

192.36

2011-12

28%
268.35
26%

2013-14

20%
2014-15

ROE

Divis Laboratories